Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases
- 31 March 2013
- journal article
- research article
- Published by Elsevier BV in Clinical Genitourinary Cancer
- Vol. 11 (1), 20-26
- https://doi.org/10.1016/j.clgc.2012.07.002
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study.Journal of Clinical Oncology, 2012
- Implications of Bone Metastases and the Benefits of Bone-Targeted TherapySeminars in Oncology, 2010
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialThe Lancet, 2010
- Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate CancerJournal of Clinical Oncology, 2010
- Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate CancerThe New England Journal of Medicine, 2004
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerThe New England Journal of Medicine, 2004
- Metastasis to bone: causes, consequences and therapeutic opportunitiesNature Reviews Cancer, 2002
- Factors regulating the growth of metastatic cancer in bone.Endocrine-Related Cancer, 1999
- Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone.Cancer and Metastasis Reviews, 1998
- Mechanisms of the development of osteoblastic metastasesCancer, 1997